Fig. 5

Effects of alisertib and volasertib in HMC-1 cells and in primary MCL cells. A Reduction of clonogenic potential of neoplastic MCs from 3 patients with MCL (green, grey and red curves) as compared to a healthy donor (HD, black curve) in the presence of increasing doses of alisertib (0.05–0.25 µM) or volasertib (0.05–0.30 µM). B Reduction of clonogenic growth of HMC-1.1 (grey) and 1.2 (red) cells in the presence of increasing doses of alisertib or volasertib (25–100 nM). All the clonogenic survival rates are expressed as mean ± standard deviation of counts from three independent experiments. C Induction of apoptosis by alisertib or volasertib (500 nM for 24 h) in HMC-1.1 (grey) and -1.2 (red), respectively. Columns represent the mean of three independent experiments and bars represent the standard error